title: Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact.
abstract: The goal of therapeutic HPV vaccines is the induction of cytotoxic T lymphocyte immunity against HPV-associated cancers. Recombinant proteins and synthetic peptides have high safety profiles but low immunogenicity, which limits their efficacy when used in a vaccine. Self-adjuvanting lipid moieties have been conjugated to synthetic peptides or expressed as lipoproteins to enhance the immunogenicity of vaccine candidates. Mono-, di- and tri-palmitoylated peptides have been demonstrated to activate dendritic cells and induce robust cellular immunity against infectious diseases and cancer. Recently, a platform technology using the high-yield production of recombinant lipoproteins with Toll-like receptor 2 agonist activity was established for the development of novel subunit vaccines. This technology represents a novel strategy for the development of therapeutic HPV vaccines. In this review, we describe recent progress in the design of therapeutic HPV vaccines using lipoimmunogens.
authors.affiliation: National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan.
authors.forename: Kuan-Yin
authors.initials: KY
authors.lastname: Shen
authors.forename: Li-Sheng
authors.initials: LS
authors.lastname: Chang
authors.forename: Chih-Hsiang
authors.initials: CH
authors.lastname: Leng
authors.forename: Shih-Jen
authors.initials: SJ
authors.lastname: Liu
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000302:isolation & purification; D000956:Antigens, Viral / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D008074:Lipoproteins / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000628:therapy*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology / Q000302:isolation & purification
chemical_list: D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D008074:Lipoproteins; D053918:Papillomavirus Vaccines; D022223:Vaccines, Subunit
keywords: HPV; Toll-like receptor 2; lipopeptide; recombinant lipoimmunogen; self-adjuvanting vaccine